Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The selective TRK inhibitor larotrectinib was approved for paediatric and adult patients with advanced TRK fusion-positive solid tumours based on a primary analysis set of 55 patients. The aim of our analysis was to explore the efficacy and long-term safety of larotrectinib in a larger population of patients with TRK fusion-positive solid tumours.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Lancet Oncol

Title: The Lancet. Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1474-5488

ISSN (Print): 1470-2045

Publication date (Electronic): April 2020

Volume: 21

Issue: 4

Affiliations

[1 ] University of Texas MD Anderson Cancer Center, Houston, TX, USA.

[2 ] Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School, Boston, MA, USA.

[3 ] Stanford University School of Medicine, Stanford University, Palo Alto, CA, USA.

[4 ] Massachusetts General Hospital, Boston, MA, USA.

[5 ] Seattle Children's Hospital, University of Washington, Seattle, WA, USA.

[6 ] Rigshospitalet, Copenhagen University, Copenhagen, Denmark.

[7 ] Hopp Children's Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany.

[8 ] Nemours Children's Hospital, Orlando, FL, USA.

[9 ] Vanderbilt University Medical Center, Nashville, TN, USA.

[10 ] David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, USA.

[11 ] Saban Research Institute, Children's Hospital Los Angeles, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA.

[12 ] Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay, Villejuif, France.

[13 ] University Hospitals Cleveland Medical Center, Cleveland, OH, USA.

[14 ] St Jude Children's Research Hospital, Memphis, TN, USA.

[15 ] Klinikum Stuttgart-Olgahospital, Stuttgart Cancer Center, Pediatrics 5 (Oncology, Hematology, Immunology), Stuttgart, Germany.

[16 ] SIREDO Center Care, Innovation, Research In Pediatric, Adolescent and Young Adult Oncology, Institut Curie and Paris Descartes University, Paris, France.

[17 ] St Vincent's University Hospital and Cancer Trials Ireland, Dublin, Ireland.

[18 ] University of Chicago, Chicago, IL, USA.

[19 ] Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA, USA.

[20 ] National Cancer Center Hospital East, Kashiwa, Japan.

[21 ] Hopp Children's Cancer Center Heidelberg, Heidelberg University Hospital, Heidelberg, Germany; German Cancer Research Center, Heidelberg, Germany; German Cancer Network, Heidelberg, Germany.

[22 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA.

[23 ] Seattle Children's Hospital, Seattle, WA, USA.

[24 ] Bayer HealthCare Pharmaceuticals, Whippany, NJ, USA.

[25 ] University of Texas Southwestern Medical Center/Children's Health, Dallas, TX, USA.

[26 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA.

[27 ] Memorial Sloan Kettering Cancer Center, New York, NY, USA; Weill Cornell Medical College, New York, NY, USA. Electronic address: drilona@mskcc.org.

Article

Publisher Item ID: S1470-2045(19)30856-3 Mid ID: NIHMS1620306

DOI: 10.1016/S1470-2045(19)30856-3

PMC ID: 7497841

PubMed ID: 32105622

SO-VID: 514c6287-c2e3-4fe4-ac6d-675a364d4fad

History

Data availability:

Comments

Comment on this article

scite_

Cited by 317

See all cited by